


RealRate


PHARMACEUTICAL 2022



CATALYST PHARMACEUTICALS INC. Rank 22 of 466







The relative strengths and weaknesses of CATALYST PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CATALYST PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 106% points. The greatest weakness of CATALYST PHARMACEUTICALS INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 294%, being 216% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	210,106
Cost of Goods Sold	21,884
Intangible Assets	0
Liabilities, Current	27,063
Liabilities, Non-Current	3,894
Other Assets	26,723
Other Compr. Net Income	-179
Other Expenses	13,185
Other Liabilities	0
Other Net Income	282
Other Revenues	140,833
Property and Equipment	959
Research and Development	16,936
Selling, General and Administrative Expense	49,628

Output Variable	Value in 1000 USD
Assets	237,788
Liabilities	30,957
Expenses	101,633
Revenues	140,833
Stockholders Equity	206,831
Net Income	39,482
Comprehensive Net Income	39,392
Economic Capital Ratio	294%

